Laos ElementoPharma Co., Ltd. (referred to as ElementoPharma) was established in 2019, with a construction area of 2500 square meters. Located in “Belt and Road” Bridgehead Comprehensive Duty Free Zone 1-1, Laos-China Boten Special Economic Zone, it is a generic drug company with huge potential in Laos.

ElementoPharma has a technical team consisting of deputy dean of Institute of Artificial Intelligence Biomedical Technology, Nanjing University, China, professors of industry, and PhDs in Cell Biology of the Chinese Academy of Sciences. It has advanced plant and other facilities designed and constructed in strict accordance with EU standards. It is equipped with advanced scientific research equipment, color steel plate purification plant, pharmaceutical purification air-conditioning system and air supply and return air systems to ensure a clean production environment, which fully conforms to production management regulations and technical standards all over the world including Laos GMP, EU GMP, American GMP and Chinese GMP.

ElementoPharma has now developed into a comprehensive pharmaceutical company integrating imitation, production, sales and after-sales service of drugs. It is strictly following GMP regulations for production and it strictly implements standards of USP and EP in drug quality.

ElementoPharma makes full use of Laos’s domestic patent compulsory licensing legal system and utilizes WTO’s exemption for compulsory patent protection for pharmaceutical products in underdeveloped countries. Currently, 10 varieties of drugs have been completed in its oral solid preparation workshop for its Phase-I project and over ten other drugs are under development. To satisfy the increasingly growing global and local demand, the liquid preparation workshop of its Phase-II project has also been completed.

Drugs produced by ElementoPharma can meet the domestic needs in Laos; in addition, drugs will be used in Boten Special Economic Zone and exported to third world countries.